ClinicalTrials.gg
RecruitingNCT07109401Updated Aug 7, 2025

Perioperative Immunotherapy for Resectable Limited-Stage SCLC

A Phase 2 interventional study of Tislelizumab (BGB-A317) Plus Chemotherapy (Cisplatin/Carboplatin and Etoposide) in Perioperative Immunotherapy, Limited Stage Lung Small Cell Carcinoma and Resectable Small Cell Lung Cancer, sponsored by Fudan University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-08-07.

Sponsored by Fudan University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Mar 2025, registered Jul 2025).
  • Started Mar 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
37
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

For limited-stage small cell lung cancer (SCLC), surgical treatment is recommended for patients with T1-2N0M0 (I-IIA) by guidelines. However, whether perioperative immunotherapy extends radical surgery to stage IIB-IIIB patients with improved survival remains elusive.

This is a phase II, single-arm study to evaluate the efficacy and safety of neoadjuvant Tislelizumab + chemotherapy (Cisplatin/Carboplatin + Etoposide) followed by radical surgery and adjuvant Tislelizumab ± chemotherapy for patients with limited-stage SCLC.

02

Conditions studied

  • Perioperative Immunotherapy
  • Limited Stage Lung Small Cell Carcinoma
  • Resectable Small Cell Lung Cancer
03

In context

Carcinoma, Small Cell

69 studies on the registry are indexed under Carcinoma, Small Cell; 13 are open to participants now.

This study's planned enrollment of 37 is close to the median of 38 across 61 interventional studies indexed under Carcinoma, Small Cell.

Browse Carcinoma, Small Cell studies →

Lead sponsor

Fudan University is the lead sponsor of 1,319 studies on the registry; 647 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Able to provide written and understand and agree to comply with the study requirements and assessment schedule;
  2. Aged 18-75 years at the time of signing the informed consent form;
  3. Pathologically (histologically or cytologically) confirmed diagnosis of small cell lung cancer;
  4. Limited-stage disease (stage IIB-IIIB according to AJCC 8th edition) assessed by bronchoscopy, PET-CT, endobronchial ultrasound (EBUS), mediastinoscopy, or percutaneous , deemed resectable with curative intent (R0 resection) by the investigator.

    TNM staging includes T3-4 (N0 only) or N1-2 (any T) and M0, where T4 is limited to tumors >7 cm in diameter; Patients with tumors invading the diaphragm, mediastinum, heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, carina or having separate tumor nodules in different ipsilateral lobes are excluded. N2 is limited to single station and non-bulky.

  5. No prior radiotherapy, chemotherapy, immunotherapy, surgery or other systemic treatments;
  6. PS score of 0-1;
  7. Expected survival must be >3 months;
  8. Adequate bone marrow reserve and organ function within 30 days prior to enrollment meeting criteria for receiving platinum-based doublet chemotherapy;
  9. No for immunotherapy.

Exclusion criteria

Exclusion Criteria:

  1. Tumor histopathology indicates non-small cell lung cancer (NSCLC);
  2. Presence of clinically inactive or active ;
  3. Any history of interstitial lung disease (ILD) (including pulmonary fibrosis or radiation pneumonitis), current ILD, or suspicion of such diseases based on imaging during screening;
  4. Receiving systemic therapy within 14 days prior to the first dose of study drug;
  5. Previous radiotherapy, chemotherapy, immunotherapy, surgery, or other systemic treatments;
  6. Any active within 2 years prior to enrollment;
  7. Women who are pregnant, breastfeeding, or planning to become pregnant during the study period;
  8. Uncontrolled or significant cardiovascular disease at the time of enrollment;
  9. Active or previously recorded or inflammatory diseases before enrollment;
  10. History of active primary immunodeficiency disorders;
  11. Presence of active infections;
  12. Active bleeding disorders within ≤6 months prior to administration of the study drug, including gastrointestinal bleeding evidenced by hematemesis, severe hemoptysis, or melena;
  13. Non-healing wounds, active peptic ulcers, or fractures;
  14. Any condition that the investigator deems makes the patient unsuitable for participation in the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
37 participants (estimated)

Study arms

  • Experimental
    Perioperative Tislelizumab combined with Etoposide and Platinum-based Chemotherapy

    Neoadjuvant therapy: Tislelizumab 200mg, i.v., q3w, 2-4 cycles; Cisplatin 75mg/m2, d1 or Carboplatin AUC5-6, d1 + Etoposide 100mg/m2, d1-3, q3w, 2-4 cycles. Those resectable after neoadjuvant therapy will be treated with radical surgery. Adjuvant therapy: Patients received radical surgery will be treated with Tislelizumab plus platinum-etoposide therapy (the total cycle of perioperative chemotherapy is four), followed by Tislelizumab monotherapy for one year.

    Drug: Tislelizumab (BGB-A317) Plus Chemotherapy (Cisplatin/Carboplatin and Etoposide)

Interventions

  • DrugTislelizumab (BGB-A317) Plus Chemotherapy (Cisplatin/Carboplatin and Etoposide)

    Drug page: TislelizumabStudies of TislelizumabTislelizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Neoadjuvant therapy: Tislelizumab + Cisplatin or Carboplatin + Etoposide; Adjuvant therapy: Tislelizumab + Cisplatin or Carboplatin + Etoposide (the total cycle of perioperative chemotherapy is four), followed by Tislelizumab monotherapy for one year.

06

What researchers measure

Primary outcomes

  1. One-year Event-free Survival Rate (1-year EFS Rate)

    The proportion of patients who have not experienced an EFS event within 1 year after the first administration of the study drug. EFS (Event-Free Survival) is defined as the time from the first dose of study treatment until the first occurrence of any of the following events: objectively documented disease progression and inability to undergo radical surgery, local recurrence, distant metastasis, or death from any cause (whichever occurs first). EFS is assessed by investigators based on RECIST v1.1 (Response evaluation criteria in solid tumors v1.1) criteria within the radical curative therapy analysis set.

    Time frame: Up to 12 months

Secondary outcomes

  1. Event-free Survival (EFS)

    Event-Free Survival (EFS) - defined as the time from the first dose of study treatment until the first occurrence of any of the following events: objectively documented disease progression and inability to undergo radical surgery, local recurrence, distant metastasis, or death from any cause (whichever occurs first).

    Time frame: up to 60 months

  2. Overall Survival (OS)

    Overall Survival - defined as the time from enrollment to death of participant due to any cause. In the case of a patient who still survives at the time of analysis, the date of last contact will be taken as the censoring date.

    Time frame: up to 60 months

  3. Objective Response Rate (ORR)

    Objective Response Rate (ORR) - defined as the proportion of patients who achieve a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR), as assessed by investigators according to RECIST v1.1 criteria.

    Time frame: Up to 12 months

  4. Disease Control Rate (DCR)

    Disease Control Rate (DCR) - defined as the proportion of patients who achieve a Best Overall Response (BOR) of Complete Response (CR), Partial Response (PR), or Stable Disease (SD), as assessed by investigators according to RECIST v1.1 criteria.

    Time frame: Up to 12 months

  5. Pathological Complete Response (pCR) Rate

    Pathological Complete Response (pCR) Rate - defined as the proportion of patients who have no residual tumor in the resected primary tumor site and all resected lymph nodes after neoadjuvant therapy among those who underwent surgical resection.

    Time frame: Up to 12 months

  6. Major Pathological Response (MPR) Rate

    Major Pathological Response (MPR) Rate - defined as the proportion of patients who have ≤10% residual viable tumor cells in the resected primary tumor site and all resected lymph nodes after neoadjuvant therapy among those who underwent surgical resection.

    Time frame: Up to 12 months

  7. Pathological Downstaging Rate

    Pathological Downstaging Rate - defined as the proportion of patients who undergo surgical resection after neoadjuvant therapy and have a postoperative pathological stage that is lower than their baseline clinical tumor stage and/or lymph node involvement.

    Time frame: Up to 12 months

  8. R0 Resection Rate

    R0 Resection Rate - defined as the proportion of patients who achieve complete tumor resection (negative margins with no residual tumor cells) among those who underwent surgical resection after neoadjuvant therapy.

    Time frame: Up to 12 months

  9. Clinical Downstaging Rate

    Clinical Downstaging Rate - defined as the proportion of patients who have a reduction in tumor size and/or lymph node involvement in their clinical tumor stage after neoadjuvant therapy compared to their baseline clinical tumor stage before surgery.

    Time frame: Up to 12 months

  10. Surgical Resection Rate

    Surgical Resection Rate - defined as the proportion of patients who undergo surgical resection after neoadjuvant therapy.

    Time frame: Up to 12 months

  11. Incidence of Treatment-emergent Adverse Event (TEAE) and Immune-related Adverse Event (IrAE)

    The incidence of TEAE and IrAE will be assessed by monitoring adverse events (AEs) and serious adverse events (SAEs) as described in the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0, and by incorporating relevant physical examinations, electrocardiograms (ECGs), and laboratory tests as needed.

    Time frame: Up to 60 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The clinical data including patient characteristics, CT images and pathology images.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Mar 2028, 36 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2025
First posted
Aug 7, 2025
StartActual
Mar 1, 2025
Primary completionEst.
Mar 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Aug 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07109401
Lead sponsor
Fudan University
Responsible party
Haiquan Chen (Director in the Department of Thoracic Surgery, FUSCC, Fudan University) — Principal investigator
First posted
Aug 7, 2025
Start date
Mar 1, 2025
Primary completion
Mar 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Aug 7, 2025

Study contacts

Haiquan Chen, MD, Ph.D.
Contact
hqchen1@yahoo.com
+86-18121299888
Fangqiu Fu, MD
Contact
fufangqiu12@163.com
+86-18918768205

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tislelizumab

Start the discussion